ArticleGynecology and pelvic medicine2025
A case report of ineffective immunosuppressive therapy for MDA5 related clinically amyopathic dermatomyositis during pregnancy and literature review.
Article in Gynecology and pelvic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinically amyopathic dermatomyositis (CADM) is a type of dermatomyositis (DM) with hallmark cutaneous lesions of DM, and no muscle weakness for a prolonged period. Antibodies tests against melanoma differentiation-associated gene 5 (MDA5) was recognized to be highly specific for CADM, and is a high risk of mortality. Immunosuppressive therapy has been reported is effective. We report ineffective immunosuppressive therapy for pregnant woman complicated by CADM with MDA5 positive, which has seldom reported before. Case Description: A 43-year-old woman at a gestational age of 21 weeks, gravida 4 para 1, with dyspnea, cough, dizziness and fever, purplish-red rash on her hands, without muscle pain or weakness, was admitted to hospital. Fetal ultrasonography showed normal fetal growth. She denied any family history and had no specific past history. On day 13 of hospitalization (gestational week 22 Conclusions: MDA5-related CADM is a high fatal disease. Immunosuppressive therapies for MDA5-related CADM may be ineffective. Women with that should conceive extremely prudently. Meanwhile, pregnancy woman with MDA5-related CADM must deserves physician team's attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.